Differential effects of cytolytic T cell subsets on intracellular infection

Science

Volumn 276, Issue 5319, 1997, Pages 1684-1687

  Stenger, Steffen ^a   Mazzaccaro, Richard J ^b   Uyemura, Koichi ^a   Cho, Sungae ^a   Barnes, Peter F ^c   Rosat, Jean Pierre ^d   Sette, Alessandro ^e   Brenner, Michael B ^d   Porcelli, Steven A ^d   Bloom, Barry R ^b   Modlin, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e CYTEL CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, CD1; ANTIGENS, CD95; CELL LINE; COCULTURE TECHNIQUES; COLONY COUNT, MICROBIAL; CYTOPLASMIC GRANULES; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; GRANZYMES; HUMANS; LYMPHOCYTE ACTIVATION; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PORE FORMING CYTOTOXIC PROTEINS; SERINE ENDOPEPTIDASES; STRONTIUM; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC;

CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

EID: 0030765980     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5319.1684     Document Type: Article

References (44)

1. J. L. Flynn, M. M. Goldstein, K. J. Triebold, B. Koller, B. R. Bloom, Proc. Natl. Acad. Sci. U.S.A. 89, 12013 (1992).
2. J. Turner and H. M. Dockrell, Immunology 87, 339 (1996); G. DeLibero, I. Flesch, S. H. E. Kaufmann, Eur. J. Immunol. 18, 59 (1988); R. E. Tascon et al., Nature Med. 2, 888 (1996).
3. J. Turner and H. M. Dockrell, Immunology 87, 339 (1996); G. DeLibero, I. Flesch, S. H. E. Kaufmann, Eur. J. Immunol. 18, 59 (1988); R. E. Tascon et al., Nature Med. 2, 888 (1996).
4. J. Turner and H. M. Dockrell, Immunology 87, 339 (1996); G. DeLibero, I. Flesch, S. H. E. Kaufmann, Eur. J. Immunol. 18, 59 (1988); R. E. Tascon et al., Nature Med. 2, 888 (1996).
5. E. M. Beckman, et al., Nature 372, 691 (1994).
6. P. A. Sieling, et al., Science 269, 227 (1995).
7. + APCs. Monoclonal antibodies used for flow cytometry and blocking experiments were as follows (4): OKT6, which blocks CD1a; WM-25, which blocks CD1b; 10C3, which blocks CD1c; OKT4, which recognizes CD4; and OKT8, which recognizes CD8a; antibodies to αβ TCR (Becton-Dickinson, San Jose, CA) and to γδ TCR, LNK16, and CD16 (Serotec, Washington, DC).
8. S. Porcelli, C. T. Morita, M. B. Brenner, Nature 360, 593 (1992); J. P. Rosat, S. Porcelli, M. Brenner, unpublished results.
9. S. Porcelli, C. T. Morita, M. B. Brenner, Nature 360, 593 (1992); J. P. Rosat, S. Porcelli, M. Brenner, unpublished results.
10. 6 per well. Adherent monolayers were infected with live M. tuberculosis (virulent strain H37Rv) for 4 hours at a MOI of 5:1. Comparison of microscope counts of mycobacteria and their growth on Middlebrook 7H11 agar plates revealed a viability of the bacteria above 90%. After extensive washing, macrophages were detached, and the efficiency of infection was determined by staining a sample with auramine-rhodamine (3.77 ± 0.32 bacteria per cell, 83 ± 4% of cells infected).
11. D. Kagi et al., Nature 369, 31 (1994); B. Lowin, M. Hahne, C. Mattmann, J. Tschopp, ibid. 370, 650 (1994); H. Kojima et al., Immunity 1, 357 (1994); C. M. Walsh et al., Proc. Natl. Acad. Sci. U.S.A. 91, 10854 (1994).
12. D. Kagi et al., Nature 369, 31 (1994); B. Lowin, M. Hahne, C. Mattmann, J. Tschopp, ibid. 370, 650 (1994); H. Kojima et al., Immunity 1, 357 (1994); C. M. Walsh et al., Proc. Natl. Acad. Sci. U.S.A. 91, 10854 (1994).
13. D. Kagi et al., Nature 369, 31 (1994); B. Lowin, M. Hahne, C. Mattmann, J. Tschopp, ibid. 370, 650 (1994); H. Kojima et al., Immunity 1, 357 (1994); C. M. Walsh et al., Proc. Natl. Acad. Sci. U.S.A. 91, 10854 (1994).
14. D. Kagi et al., Nature 369, 31 (1994); B. Lowin, M. Hahne, C. Mattmann, J. Tschopp, ibid. 370, 650 (1994); H. Kojima et al., Immunity 1, 357 (1994); C. M. Walsh et al., Proc. Natl. Acad. Sci. U.S.A. 91, 10854 (1994).
15. P. A. Neighbour and H. S. Huberman, Y. Kress, Eur. J. Immunol. 12, 588 (1982); P. C. Quan, T. Ishizaka, B. R. Bloom, J. Immunol. 128, 1786 (1982); P. A. Neighbour and H. S. Huberman, ibid., p. 1236.
16. P. A. Neighbour and H. S. Huberman, Y. Kress, Eur. J. Immunol. 12, 588 (1982); P. C. Quan, T. Ishizaka, B. R. Bloom, J. Immunol. 128, 1786 (1982); P. A. Neighbour and H. S. Huberman, ibid., p. 1236.
17. P. A. Neighbour and H. S. Huberman, Y. Kress, Eur. J. Immunol. 12, 588 (1982); P. C. Quan, T. Ishizaka, B. R. Bloom, J. Immunol. 128, 1786 (1982); P. A. Neighbour and H. S. Huberman, ibid., p. 1236.
18. 2+ was chosen as a selective inhibitor of granule-dependent lysis, because the calcium chelator EGTA, which blocks the perforin pathway, also inhibits up-regulation of FasL, as required in our studies with primary human T cells.
19. Tumor necrosis factor-α (TNF-α) induces lysis of a murine fibrosarcoma cell line independently of perforin or Fas-FasL (19). This cytokine did not contribute to lysis of the CTLs used in this study because addition of blocking antibody to TNF-α did not inhibit the cytotoxicity.
20. G. Berke, Annu. Rev. Immunol. 12, 735 (1994).
21. + T cells and natural killer cells.
22. S. H. E. Kaufmann, Immunol. Today 9, 168 (1988).
23. K. Benihoud, D. Bonardelle, P. Bobe, N. Kiger, Eur. J. Immunol. 27, 415 (1997).
24. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson, Science 270, 1189 (1995); H. Yagita et al., Immunol. Rev. 146, 223 (1995).
25. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson, Science 270, 1189 (1995); H. Yagita et al., Immunol. Rev. 146, 223 (1995).
26. P. Laochumroonvorapong et al., Infect. Immun. 65, 127 (1997); A. Cooper, C. D'Souza, A. A. Frank, I. Orme, ibid., p. 1317; R. J. Mazzaccaro, J. Flynn, B. R. Bloom, unpublished results.
27. P. Laochumroonvorapong et al., Infect. Immun. 65, 127 (1997); A. Cooper, C. D'Souza, A. A. Frank, I. Orme, ibid., p. 1317; R. J. Mazzaccaro, J. Flynn, B. R. Bloom, unpublished results.
28. P. Laochumroonvorapong et al., Infect. Immun. 65, 127 (1997); A. Cooper, C. D'Souza, A. A. Frank, I. Orme, ibid., p. 1317; R. J. Mazzaccaro, J. Flynn, B. R. Bloom, unpublished results.
29. S. Pena et al., J. Immunol. 158, 2680 (1997); M. Anderson et al., EMBO J. 14, 1615 (1995); Y. Miyakawa et al., Infect Immun. 64, 926 (1996).
30. S. Pena et al., J. Immunol. 158, 2680 (1997); M. Anderson et al., EMBO J. 14, 1615 (1995); Y. Miyakawa et al., Infect Immun. 64, 926 (1996).
31. S. Pena et al., J. Immunol. 158, 2680 (1997); M. Anderson et al., EMBO J. 14, 1615 (1995); Y. Miyakawa et al., Infect Immun. 64, 926 (1996).
32. R. K. Lee, J. Spielman, D. Y. Zhao, K. J. Olsen, E. R. Podack, J. Immunol. 157, 1919 (1996); M. Y. Braun, B. Lowin, L. French, H. Acha-Orbea, J. Tschopp, J. Exp. Med. 183, 657 (1996).
33. R. K. Lee, J. Spielman, D. Y. Zhao, K. J. Olsen, E. R. Podack, J. Immunol. 157, 1919 (1996); M. Y. Braun, B. Lowin, L. French, H. Acha-Orbea, J. Tschopp, J. Exp. Med. 183, 657 (1996).
34. A. J. McMichael, F. M. Gotch, J. Santos-Aguado, J. L. Strominger, Proc. Natl. Acad. Sci. U.S.A. 85, 9194 (1988).
35. N. Kayagaki et al., J. Exp. Med. 182, 1777 (1995).
36. W. C. Liles, P. A. Kiener, J. A. Ledbetter, A. Aruffo, S. J. Klebanoff, ibid. 184, 429 (1996).
37. P. L. Coleman and G. D. Green, Methods Enzymol. 80, 408 (1981).
38. 51Cr release by macrophages in the absence of T cells was <15%.
39. 51Cr release was determined after a 4-hour incubation. Expression of Fas on the target cells was not affected by infection with M. tuberculosis, as determined by flow cytometry.
40. L-lysine thiobenzyl (BLT)-esterase in the supernatant was determined by the BLT-esterase assay (23). The supernatants (20 μl) were coincubated with 35 μl of 1 mM BLT (Sigma), 35 μl of 1 mM 5,5′-dithio-bis-(2-nitrobenzoic acid) (Sigma), and 10 μl of a 0.1% Triton X-100 (Sigma) solution. After a 30-min incubation at 37°C, the absorbance at 405 nm was determined.
41. P. Chomczynski and N. Sacchi, Anal. Biochem. 162, 156 (1987).
42. 32P and polynucleotide kinase (Boehringer Mannheim, Germany) and visualized by autoradiography.
43. E. P. Miskovsky et al., J. Immunol. 153, 2787 (1994).
44. We are indebted to M. Horwitz for use of his P3 laboratory and P. Sieling for continuous support and helpful discussions. Supported by the AIDS Stipendium; Deutsches Krebsforschungszentrum, Heidelberg (S.S.); NIH (R.L.M., S.A.P., B.R.B., M.B.B.); the Arthritis Foundation (S.A.P.); the Howard Hughes Medical Institute (B.R.B.); the Swiss Foundation for Grants in Medicine and Biology (J.-P.R); and the United Nations Development Programme-World Bank-World Health Organization Special Program for Research and Training in Tropical Diseases (IMMLEP) and the Dermatologic Research Foundation of California.